NRAS and BRAF mutation frequency in primary oral mucosal melanoma

被引:36
|
作者
Buery, Rosario Rivera [1 ,2 ]
Siar, Chong Huat [3 ]
Katase, Naoki [1 ]
Gunduz, Mehmet [4 ,5 ]
Lefeuvre, Mathieu [1 ]
Fujii, Masae [1 ]
Inoue, Masahisa [2 ]
Setsu, Kojun [2 ]
Nagatsuka, Hitoshi [1 ]
机构
[1] Okayama Univ, Dept Oral Pathol & Med, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008525, Japan
[2] Tokushima Bunri Univ, Fac Pharmaceut Sci, Labs Struct & Funct Res, Tokushima 770, Japan
[3] Univ Malaya, Fac Dent, Dept Oral Pathol Oral Med & Periodontol, Kuala Lumpur, Malaysia
[4] Fatih Univ, Fac Med, Dept Otolaryngol, Ankara, Turkey
[5] Fatih Univ, Fac Med, Dept Med Genet, Ankara, Turkey
基金
日本学术振兴会;
关键词
oral mucosal melanoma; NRAS; BRAF; mutation; immunohistochemistry; KIT GENE; B-RAF; ACTIVATION; INHIBITION; EXPRESSION; SUBTYPES; KINASE; METASTASES; RESISTANCE; UNCOMMON;
D O I
10.3892/or.2011.1385
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Oral mucosal melanoma (OMM) is a fatal sarcoma of unknown etiology. Histological morphology and genetic events are distinct from those of its cutaneous counterpart. Mutation and up-regulation of c-kit has been identified in OMM which may activate downstream molecules such as RAS and RAF. These molecules are involved in the mitogen-activated protein kinase (MAPK) pathway leading to tremendous cell proliferation and survival. NRAS and BRAF mutation and protein expression have been studied in other melanoma subtypes. The purpose of this study was to determine RAS protein expression and NRAS and BRAF mutation in 18 primary OMM cases using immunohistochemistry and mutation analysis. Results showed that RAS is intensely expressed in both in situ and invasive OMMs. However, NRAS mutation was only observed in 2/15 polymerase chain reaction (PCR) amplified cases both of which were silent mutations. On the other hand, BRAF missense mutations were observed only in 1/15 cases with PCR amplification. NRAS and BRAF mutations were independent from previously reported c-kit mutations. The classical V600E BRAF mutation was not found; instead a novel V600L was observed suggesting that the oncogenic event in OMM is different from that in skin melanoma. The low frequency of NRAS and BRAF mutations indicate that these genes are not common, but probable events in OMM pathogenesis, most likely independent of c-kit mutation.
引用
收藏
页码:783 / 787
页数:5
相关论文
共 50 条
  • [1] Primary oral mucosal melanoma: Are NRAS and BRAF mutations determinant in its pathogenesis?
    Nico, M. Menta S.
    Hsieh, R.
    Camillo-Coutinho, C.
    Fernandes, J. Dumet
    Lourenco, S. V.
    VIRCHOWS ARCHIV, 2014, 465 : S14 - S14
  • [2] Mutational Status of NRAS and BRAF Genes and Protein Expression Analysis in a Series of Primary Oral Mucosal Melanoma
    Hsieh, Ricardo
    Nico, Marcello M. S.
    Camillo, Claudia M. C.
    Oliveira, Katia K.
    Sangueza, Martin
    Lourenco, Silvia V.
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2017, 39 (02) : 104 - 110
  • [3] Atypical BRAF and NRAS Mutations in Mucosal Melanoma
    Dumaz, Nicolas
    Jouenne, Fanelie
    Delyon, Julie
    Mourah, Samia
    Bensussan, Armand
    Lebbe, Celeste
    CANCERS, 2019, 11 (08)
  • [4] Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases
    Lyu, Jiong
    Wu, Yunteng
    Li, Chaojun
    Wang, Runxiang
    Song, Hao
    Ren, Guoxin
    Guo, Wei
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2016, 45 (04) : 295 - 301
  • [5] BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
    Colombino, Maria
    Capone, Mariaelena
    Lissia, Amelia
    Cossu, Antonio
    Rubino, Corrado
    De Giorgi, Vincenzo
    Massi, Daniela
    Fonsatti, Ester
    Staibano, Stefania
    Nappi, Oscar
    Pagani, Elena
    Casula, Milena
    Manca, Antonella
    Sini, MariaCristina
    Franco, Renato
    Botti, Gerardo
    Caraco, Corrado
    Mozzillo, Nicola
    Ascierto, Paolo A.
    Palmieri, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (20) : 2522 - 2529
  • [6] Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma
    Pozzobon, F. C.
    Puig-Butille, J. A.
    Gonzalez-Alvarez, T.
    Carrera, C.
    Aguilera, P.
    Alos, L.
    Badenas, C.
    Grichnik, J. M.
    Malvehy, J.
    Puig, S.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (04) : 754 - 759
  • [7] Analysis of BRAF, NRAS and PI3K mutation in primary and metastatic melanoma
    Libra, Massimo
    Malaponte, Grazia
    Callari, Daniela
    D'Assoro, Antonio
    Travali, Salvatore
    Mazzarino, Maria C.
    McCubrey, James A.
    Stivala, Franca
    CANCER RESEARCH, 2006, 66 (08)
  • [8] Mutation frequency in BRAF and NRAS genes among primary tumors and different types of metastasis from melanoma patients.
    Colombino, M.
    Capone, M.
    Maio, M.
    De Giorgi, V.
    Cossu, A.
    Lissia, A.
    Rubino, C.
    Massidda, B.
    Staibano, S.
    Nappi, O.
    Botti, G.
    Caraco, C.
    Mozzillo, N.
    Manca, A.
    Sini, M.
    Ascierto, P. A.
    Palmieri, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] KIT, NRAS, BRAF and FMNL2 mutations in oral mucosal melanoma and a systematic review of the literature
    Chen, Feng
    Zhang, Qian
    Wang, Yanjin
    Wang, Siwen
    Feng, Shawein
    Qi, Liyuan
    Li, Xuefen
    Ding, Chong
    ONCOLOGY LETTERS, 2018, 15 (06) : 9786 - 9792
  • [10] A novel BRAF mutation in association with primary amelanotic melanoma with oral metastases
    Zalaudek, I.
    Ciarrocchi, A.
    Piana, S.
    Argenziano, G.
    Torricelli, F.
    Sancisi, V.
    Gandolfi, G.
    Longo, C.
    Moscarella, E.
    Banzi, C.
    Nicoli, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2015, 29 (02) : 387 - 390